A pilot study on the cutaneous toxicities in oncology patients on Epidermal Growth Factor Receptor inhibitors: skin physiology, clincial manifestations and quality of life.

Quantifying physiological skin changes and quality of life in oncology patients on epidermal growth factor receptor inhibitors (EGFRIs) compared to normal participants not on EGFRIs. Can physiological skin changes be used to quantify cutaneous toxicities and evaluate subclinical changes before overt disease in order to prevent and minimise these side effects.

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12608000265370

Enrollment

Registered

2008-05-26

Start date

2008-06-15

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Epidermal growth factor receptor inhibitors (EGFRIs) have been shown efficacy in the treatment of several cancers but despite their potential to be revolutionary therapeutic agents, they are commonly associated with undesirable skin side effects, some of which are chronic or have profound physical and psychosocial impact on patients. This study aims to assess physiological skin changes in patients on EGFRIs using transepidermal water loss (TEWL), skin pH, skin sebum levels, skin surface hydration and surface perfusion measurements in conjunction with microbiology swabs, clinical photography and the Dermatology Quality of Life Index (DQLI) in order to understand the pathophysiology of cutaneous side effects, better characterise these toxicities using a refined classification system and evaluate subclinical changes before overt disease in order to prevent and minimise cutaneous side effects.

Interventions

A pilot study assessing physiological skin changes using transepidermal water loss (TEWL), skin pH, skin surface hydration, skin sebum levels, skin surface perfusion and microbiological swabs and culture in conjunction with clinical photography and the Dermatology Quality of Life Index (DQLI) in oncology patients on EGFRIs for a period of 3 months.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Oncology patients about to start EGFRIs male or female aged 18 years or above willing to give informed consent

Exclusion criteria

Younger than 18 years of age severe underlying disease that may interfere with the testing or test results

Outcome results